A Phase 2, placebo-controlled trial for hamstring strain is currently recruiting but has not reported results
doi:10.1056/NEJMoa030656
NO is an endogenously produced vasodilator and is largely implicated in hemostatic mechanisms [39] while, in tail amputation and heparin-/warfarin-administration models, both the NO-synthase (NOS)-blocker, L-NAME (thought to have a prothrombotic effect) [3] and NOS-substrate, L-arginine [presented with an antithrombotic effect) [3] were little investigated
Derived from a protein found in gastric juice, BPC-157 has demonstrated remarkable healing properties across a broad range of tissues in preclinical studies, including tendons, ligaments, muscles, bone, and the gastrointestinal tract
However, it remains unapproved by the FDA and banned for human use in many countries due to the lack of human trials and concerns over safety, contamination, and legal misuse